Indian MASLD Genetics - APOC3 May Influence Susceptibility, While PNPLA3 Tracks Fibrosis Progression: JCEH | August 2026

Introduction:

MASLD affects a large proportion of Indian adults, but genetic drivers may differ by ancestry and may influence different stages of disease. This North Indian candidate-gene study examined whether specific variants are associated with developing MASLD itself versus progressing to significant fibrosis.

Why was this study needed?

Most MASLD genetic data come from non-Indian populations.

Genetic variants may influence disease susceptibility and fibrosis progression differently.

Ancestry-specific risk profiling could improve future personalized stratification in Indian patients.

Results:

69 patients with MASLD were genotyped for 12 candidate SNPs; 38 had LSM ≥8 kPa.

PNPLA3 rs738409 G was the strongest predictor of significant fibrosis (OR 2.89); carriers had higher median LSM (15.6 vs 7.5 kPa).

APOC3 rs2854116 T was significantly enriched compared with the Indian reference population (64.0% vs 47.9%; OR 1.93) but showed no association with fibrosis.

SAMM50 and FTO showed suggestive but non-significant signals.

Clinical Impact:

The key finding is a possible genetic dissociation:

APOC3 → susceptibility to MASLD

PNPLA3 → fibrosis progression once MASLD is established

This supports the idea that not all genetic variants contribute to the same phase of disease biology.

However, this is an exploratory, single-centre study with only 69 patients, and fibrosis was classified by liver stiffness rather than histology. The APOC3 finding also comes from comparison with population reference data rather than matched controls.

Bottom Line:

In this North Indian MASLD cohort, APOC3 rs2854116 appeared more relevant to disease susceptibility, whereas PNPLA3 rs738409 was strongly associated with fibrosis severity. The findings are hypothesis-generating and support larger ancestry-specific validation before genetic testing can influence routine MASLD management.